3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
5
Triple Negative Breast Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Breast Neoplasms
2
Uveal Melanoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma
1
Liposarcoma
1
Fallopian Tube Neoplasms
1
Carcinoma, Squamous Cell
1
Anatomic Stage III Breast Cancer AJCC v8
1
Interventions
Gemcitabine
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tanespimycin
1
selinexor
1
pembrolizumab
1
olaparib
1
ixazomib
1
Glutamine
1
Fulvestrant
1
Adjuvants, Pharmaceutic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Liposarcoma
×
olaparib
×
Clear all
NCT06116578
2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Withdrawn